|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||35.92 - 41.20|
|52 Week Range||25.07 - 139.99|
|Beta (5Y Monthly)||1.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.83|
Subscribe to Yahoo Finance Plus to view Fair Value for TWST
SOUTH SAN FRANCISCO, Calif. & SEOUL, South Korea, June 30, 2022--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ildong Pharmaceutical, today announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology.
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Jazz Pharmaceuticals (NASDAQ: JAZZ), and Twist Bioscience (NASDAQ: TWST). Prosper Junior Bakiny (Axsome Therapeutics): Investors intent on doubling their money by 2025 might benefit from looking at stocks that seem wildly undervalued and could experience multiple catalysts in the next couple of years. Axsome Therapeutics lagged the market in recent months, primarily because of regulatory roadblocks.